文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

静脉给予长效DNase I(PRX-119)在多微生物腹腔脓毒症小鼠模型中的疗效

Intravenous Delivery of Long-Acting Dnase I (PRX-119) In a Murine Model of Polymicrobial Abdominal Sepsis.
PubMed 文献 · Shock · 2025-07-08
一句话结论小鼠腹腔脓毒症模型中,静脉注射长效DNase I(PRX-119)可改善生存率、减少免疫血栓形成和器官损伤,且无需频繁给药。

本研究在C57Bl/6小鼠(10–12周龄)中采用盲肠结扎穿孔(CLP)模型诱导多微生物腹腔脓毒症,并给予临床相关支持治疗(抗生素、液体复苏)。静脉注射PRX-119(1 mg/kg)在72小时和7天生存研究中测试疗效,同时检测血浆cfDNA、IL-6、IL-10、凝血酶-抗凝血酶(TAT)复合物、生理参数、细菌负荷、肺髓过氧化物酶及器官损伤/功能。结果显示,单次给药(T=8 h)或两次给药(T=4和24 h)改善72小时生存率;雄性小鼠中三次给药(CLP后T=4、20、36 h)提供7天持续保护效应;PRX-119降低cfDNA、IL-6、TAT、肺髓过氧化物酶和细菌负荷,并减轻器官损伤。结论认为静脉给予PRX-119改善生存率、减少免疫血栓形成和器官损伤,且无需频繁注射。

要点

  • 在CLP诱导的多微生物腹腔脓毒症小鼠中,静脉注射PRX-119(1 mg/kg)单次(T=8 h)或两次(T=4和24 h)给药改善72小时生存率。
  • 雄性小鼠中,三次给药(CLP后T=4、20、36 h)提供7天持续保护效应。
  • PRX-119治疗降低血浆cfDNA、IL-6、TAT复合物、肺髓过氧化物酶和细菌负荷。
  • PRX-119治疗减轻器官损伤。
  • PRX-119为PEG化重组人DNase I,半衰期约12小时,支持无需频繁给药的方案。

适用人群与场景

  • C57Bl/6小鼠(10–12周龄),采用盲肠结扎穿孔(CLP)模型诱导多微生物腹腔脓毒症,并给予临床相关支持治疗(抗生素、液体复苏)。

处置流程与药物剂量

  • 静脉注射PRX-119 1 mg/kg:单次给药在T=8 h,或两次给药在T=4和24 h,用于72小时生存研究。
  • 静脉注射PRX-119 1 mg/kg:三次给药在CLP后T=4、20和36 h,用于雄性小鼠7天生存研究。

研究设计与关键结果

  • 研究类型:动物实验(小鼠CLP脓毒症模型);样本量未报告;人群:C57Bl/6小鼠(10–12周龄),使用雌雄两性。
  • 干预与对照:静脉注射PRX-119(1 mg/kg) vs 对照(未明确描述对照);主要终点:72小时和7天生存率。
  • 单次给药(T=8 h)或两次给药(T=4和24 h)改善72小时生存率;雄性小鼠三次给药(T=4、20、36 h)提供7天持续保护效应。
  • PRX-119降低cfDNA、IL-6、TAT、肺髓过氧化物酶和细菌负荷,并减轻器官损伤。

证据类型、等级与局限

  • 证据类型:动物实验(小鼠模型);证据等级未报告;局限:原文未报告局限性。

对床旁实践的改变

  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Sepsis is a life-threatening complication of infection in which a dysregulated host response precipitates multiorgan dysfunction. Neutrophil extracellular traps contribute to infection-induced immunothrombosis by releasing cell-free DNA (cfDNA), which provides a prothrombotic scaffold for blood clots. Although DNase I has therapeutic promise due to its ability to degrade cfDNA, its short plasma half-life (2 to 4 h) may necessitate multiple daily injections, potentially posing challenges for clinical use. This study investigates the efficacy of i.v. administration of PRX-119, a PEGylated recombinant human DNase I with an extended half-life of ~12 h.

METHODS: Sepsis was induced in C57Bl/6 mice (10-12 weeks old) using the cecal ligation and puncture (CLP) model. The efficacy of i.v. PRX-119 (1 mg/kg) was tested in 72-h and 7-day survival studies, including clinically relevant supportive therapies (antibiotics, fluid resuscitation). We measured plasma levels of cfDNA, IL-6, IL-10, and thrombin-antithrombin (TAT) complexes. We assessed physiological parameters, bacterial burden, lung myeloperoxidase, and organ injury/function.

RESULTS: Using both sexes, a single dose of PRX-119 (at T = 8 h) or two doses (at T = 4 and 24 h) improved survival at 72 h. Using male mice, we observed that three doses (at T = 4, 20, and 36 post-CLP) provided a sustained protective effect at 7 days post-CLP. PRX-119 treatment reduced cfDNA, IL-6, TAT, lung myeloperoxidase, and bacterial load. PRX-119 treatment also reduced organ injury.

CONCLUSIONS: Intravenous delivery of PRX-119 improved survival and reduced immunothrombosis and organ injury, without the need for frequent injections.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Sharma N, Dwivedi DJ, Fux L, et al. Intravenous Delivery of Long-Acting Dnase I (PRX-119) In a Murine Model of Polymicrobial Abdominal Sepsis. Shock. 2025. PMID: 40705350. doi:10.1097/SHK.0000000000002666

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。